Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery.

ABSTRACT: The epidermal growth factor-epidermal growth factor receptor (EGF-EGFR) pathway has become the main focus of selective chemotherapeutic intervention. As a result, two classes of EGFR inhibitors have been clinically approved, namely monoclonal antibodies and small molecule kinase inhibitors. Despite an initial good response rate to these drugs, most patients develop drug resistance. Therefore, new treatment approaches are needed. In this work, we aimed to find a new EGFR-specific, short cyclic peptide, which could be used for targeted drug delivery. Phage display peptide technology and biopanning were applied to three EGFR expressing cells, including cells expressing the EGFRvIII mutation. DNA from the internalized phage was extracted and the peptide inserts were sequenced using next-genera

SUBMITTER: Furman O 

PROVIDER: S-EPMC9318536 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature